| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
5-Methylresorcinol monohydrate does not have a specific defined biological target in the context of drug development. It is a simple phenolic compound that can act as a substrate for various enzymes including tyrosinase, laccase, and polyphenol oxidase. In vitro studies have shown that it is cytotoxic to certain cell lines, but no specific receptor or enzyme target is identified for its cytotoxic effects. It is primarily used as a chemical intermediate, research chemical, and biological reagent rather than as a drug with a specific target.
|
|---|---|
| ln Vitro |
5-Methylresorcinol monohydrate (Orcinol monohydrate) (100, 200, 500 µM; 24, 72 h) is cytotoxic to B16 and Hs68 cells [1].
In vitro, 5-Methylresorcinol monohydrate (orcinol monohydrate) has been evaluated for its cytotoxic effects on B16 (mouse melanoma) and Hsa68 cells. At concentrations of 100, 200, and 500 microM, and incubation times of 24 and 72 hours, the compound exhibited cytotoxicity against these cell lines. No specific IC50 values are reported, and no other biological activities (e.g., enzyme inhibition, receptor binding) are described in the search results. The compound is primarily a chemical reagent and not a potent drug candidate. |
| ln Vivo |
5-Methylresorcinol monohydrate (2.5, 5 mg/kg; po) has anxiolytic activity but no sedative effects [2].
No specific in vivo activity data for 5-Methylresorcinol monohydrate are reported in the search results. It has not been evaluated as a therapeutic agent in animal models. Its primary use is as a chemical reagent and research chemical. While orcinol (non-hydrated) has been used in some biochemical assays (e.g., orcinol test for pentoses), there are no reports of its in vivo efficacy. The monohydrate form is simply a crystalline form of the compound. |
| Enzyme Assay |
5-Methylresorcinol monohydrate is not evaluated in enzyme/receptor binding assays as it is not a drug candidate. It can be used as a substrate to measure the activity of phenol-oxidizing enzymes such as tyrosinase, laccase, and polyphenol oxidase. In such assays, the compound is incubated with the enzyme, and the formation of oxidized products is monitored by absorbance (e.g., at 400-500 nm). However, no specific binding assays are conducted for this compound as a drug. The compound is characterized by GC (purity >98%), NMR, and water content analysis (11.0-14.0%).
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: B16, Hs68 Tested Concentrations: 100, 200, 500 µM Incubation Duration: 24, 72 h Experimental Results: Showed cytotoxicity with the inhibition rate of 101.7% for Hs68 cells at 24 h and 104.4% inhibition rate for B16 cells at 72 h. For cytotoxicity assays, B16 (mouse melanoma) and Hsa68 cells are seeded in 96-well plates (10,000 cells/well) and incubated at 37degC overnight. The medium is replaced with fresh medium containing 5-Methylresorcinol monohydrate at concentrations of 100, 200, and 500 microM. Control wells receive vehicle (e.g., DMSO or water). After 24 or 72 hours of incubation, cell viability is assessed by the MTT assay: MTT solution is added to each well, and after 2-4 hours of incubation, the formazan product is dissolved in DMSO, and absorbance is measured at 570 nm. The percentage of viable cells is calculated relative to the vehicle control. Cytotoxicity is observed at 100-500 microM concentrations. |
| Animal Protocol |
Animal/Disease Models:18-22 g Male CD-1 mice[2]
Doses: 2.5, 5 mg/kg Route of Administration: P.o. Experimental Results: Increased the time spent in open arms and the number of entries into open arms in the elevated plus-maze test, increased the number of head-dips in the hole-board test; did not significantly affect the locomotion of mice in the open-field test. No animal experiments for 5-Methylresorcinol monohydrate are described in the search results. As a simple phenolic compound and chemical reagent, it is not typically administered to animals for efficacy studies. If used in in vivo studies, it would likely be for toxicological evaluation rather than therapeutic efficacy. Standard acute toxicity testing in rodents could be performed, but no such data are reported. The compound is not intended for in vivo use as a drug. |
| ADME/Pharmacokinetics |
5-Methylresorcinol monohydrate (C₇H₈O2·H2O, MW = 124.14 + 18.02 = 142.16) is a solid powder. Appearance: white to light yellow to light orange powder or crystals. Purity by GC: min. 98.0%. Water content: 11.0-14.0% (indicative of the monohydrate form). For storage, the compound should be kept at room temperature in a sealed container, away from moisture and light. For in vitro use, it is soluble in water and organic solvents (ethanol, DMSO). Stock solutions can be prepared in DMSO (100-500 mM). No PK data are reported.
|
| Toxicity/Toxicokinetics |
In vitro cytotoxicity studies indicate that 5-Methylresorcinol monohydrate is cytotoxic to B16 and Hsa68 cells at concentrations of 100-500 microM, suggesting potential cellular toxicity. No formal toxicity studies (LD50, target organ toxicity) are reported. As a research-grade chemical, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling chemicals should be followed, including the use of gloves, lab coat, and safety goggles. Orcinol (5-methylresorcinol) is known to be a skin, eye, and respiratory tract irritant.
|
| References | |
| Additional Infomation |
5-Methylresorcinol monohydrate (orcinol monohydrate) is the monohydrate form of orcinol, a naturally occurring phenolic compound found in lichens. Orcinol is used in the orcinol test for the detection and quantification of pentoses (e.g., RNA). In this colorimetric test, pentoses are converted to furfural, which reacts with orcinol to produce a blue-green color. Orcinol is also a chemical intermediate for the synthesis of various dyes and pharmaceutical compounds. The monohydrate form is a crystalline solid that is stable and easy to handle. The compound is for research and laboratory use only and has no therapeutic applications. It has not received regulatory approval for any medical indication.
|
| Molecular Formula |
C7H10O3
|
|---|---|
| Molecular Weight |
142.15
|
| Exact Mass |
142.062
|
| CAS # |
6153-39-5
|
| PubChem CID |
3083941
|
| Appearance |
Solid powder
|
| Boiling Point |
290 °C
|
| Melting Point |
56-61 °C
|
| Flash Point |
147°C/5mm
|
| LogP |
1.341
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
82.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C([H])=C(C([H])=C(C([H])([H])[H])C=1[H])O[H].O([H])[H]
|
| InChi Key |
NBKPNAMTHBIMLA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8O2.H2O/c1-5-2-6(8)4-7(9)3-5;/h2-4,8-9H,1H3;1H2
|
| Chemical Name |
5-methylbenzene-1,3-diol;hydrate
|
| Synonyms |
Orcinol monohydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.0348 mL | 35.1741 mL | 70.3482 mL | |
| 5 mM | 1.4070 mL | 7.0348 mL | 14.0696 mL | |
| 10 mM | 0.7035 mL | 3.5174 mL | 7.0348 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
